Drug Trial Radar · NCT05952596
A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults
Last checked: Nov 20, 2026Latest source record: Jul 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
42
Planned (sponsor's estimate)
Start
Jul 17, 2023
Primary completion
Oct 31, 2023
Study completion Mar 31, 2024
Sponsor
- Lead sponsor
- LG ChemIndustry
- Sponsor type
- Industry
- First posted
- Jul 19, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-center, randomized, active-controlled, parallel-design, double-blind, phase I study to evaluate the safety and immunogenicity of a single dose of APV006 in healthy adults.
Conditions
- Diphtheria
- Tetanus
- Pertussis
- Poliomyelitis
- Hepatitis B
- Haemophilus Influenzae Type b Infection
Interventions
DTaP-HepB-IPV-Hib vaccineBiological
Hexavalent vaccine (DTaP-HepB-IPV-Hib vaccine: Diphtheria-Tetanus-Acelluar Pertussis-Hepatitis B-Sabin Inactivated Poliovirus-Haemophilus influenzae type b vaccine)
DTaP-HepB-IPV-Hib vaccineBiological
Hexavalent vaccine (DTaP-HepB-IPV-Hib vaccine: Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-poliomyelitis(inactived)-Haemophilus influenzae type b vaccine)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects with immediate reactionsTime frame: For 30 minutes after the vaccination
- Number of subjects with solicited adverse eventsTime frame: For 7 days after the vaccination [Day 1-8]
- Number of subjects with unsolicited adverse eventsTime frame: For 28 days (+7 days of window period) after the vaccination [Day 1-29]
- Number of subjects with serious adverse eventsTime frame: For 181 days (+7 days of window period) after the vaccination [Day 1-181]
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.